Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors

BACKGROUND: High-dose chemotherapy (HDC) using sequential cycles of carboplatin/etoposide is curative for relapsed germ-cell tumors (GCT). However, outcomes of high-risk patients in advanced relapse remain poor. We previously developed a new HDC regimen combining infusional gemcitabine with docetaxe...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Oncol
Glavni autori: Nieto, Y., Tu, S. -M., Bassett, R., Jones, R. B., Gulbis, A. M., Tannir, N., Kingham, A., Ledesma, C., Margolin, K., Holmberg, L., Champlin, R., Pagliaro, L.
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2015
Teme:
Original Articles
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5006186/
https://ncbi.nlm.nih.gov/pubmed/26199392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv310
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items